Finoriq research workspace
Oruka Therapeutics, Inc. (ORKA) SEC Filings & Filing Highlights
Oruka Therapeutics, Inc. also develops ORKA-003 for targeting an undisclosed pathway. Review ORKA SEC filings, filing highlights, and disclosure activity on Finoriq.
Company Snapshot
Oruka Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing novel monoclonal antibody therapeutics for psoriasis (PsO), and other inflammatory and immunology (I&I) indications. Its lead products include ORKA-001 that targets p19 subunit of interleukin-23, which is in phase 2a trial for the treatment of PsO; and ORKA-002 that targets interleukin-17A and interleukin-17F, which is in phase 2 trial for the treatment of PsO, psoriatic arthritis, and other conditions. The company also develops ORKA-003 for targeting an undisclosed pathway; and ORKA-021, a sequential combination regimen of ORKA-002 and ORKA-001. Oruka Therapeutics, Inc. is headquartered in Menlo Park, California.
- Company
- Oruka Therapeutics, Inc. (ORKA)
- Ticker
- ORKA
- Market Cap
- $5.7B
- Latest Price
- $94.17
- Industry
- Diagnostics
Oruka Therapeutics, Inc. (ORKA) Recent SEC Filing Highlights
Recent SEC filings, filing events, and disclosure highlights indexed for Oruka Therapeutics, Inc. (ORKA).
| Event | Form | Date |
|---|---|---|
| On June 2, 2026, Oruka Therapeutics, Inc. held its Annual Meeting of Stockholders. Set forth be...On June 2, 2026, Oruka Therapeutics, Inc. (the “Company”) held its Annual Meeting of Stockholders (the “Annual Meeting”). Set forth below i... | 8-K5.07 | 2026-06-04 |
| Oruka Therapeutics, Inc.: Corporate updateOn May 29, 2026, Oruka Therapeutics, Inc. (the “Company”) entered into the First Amendment to IL-23 License Agreement (the “Amendment”), am... | 8-K8.01 | 2026-06-01 |
| Recent DevelopmentsCertain Financial and Operating Data for First Quarter 2026 | 8-K8.01 | 2026-04-30 |
| Recent DevelopmentsCertain Financial and Operating Data for First Quarter 2026 | 8-K2.02 | 2026-04-30 |
| Oruka Therapeutics Announces Positive Week 16 Data for ORKA-001 from the OngoingOruka Therapeutics Announces Positive Week 16 Data for ORKA-001 from the Ongoing | 8-K8.01 | 2026-04-27 |
Live data loads in the app
This static page shell gives search engines reliable page context. Current tables, filings, charts, and market data continue to load from Finoriq APIs after the application starts.